BioCentury
ARTICLE | Clinical News

SM88: Phase Ib/II started

June 20, 2016 7:00 AM UTC

Tyme began an open-label, dose-escalation, dose-expansion, U.S. Phase Ib/II trial to evaluate SM-88 in up to 54 patients who failed previous androgen deprivation therapy. ...